Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Copenhagen University Hospital, Rigshospitalet
Colorectal cancer patients with 1-3 liver metastases (diameter ≤4.0 cm) found unsuitable for resection are randomized 1:1 to either MWA or SBRT. Chemotherapy is allowed. Curative treatment of extrahepatic disease must be initiated in patients with lung metastases and/or primary tumors. Patients will be analyzed according to the intention-to-treat principle.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Colorectal cancer patients with oligo metastatic disease in the liver (1 to 3 tumors), and where metastases are found unsuitable for resection because of
1. non-resectability
2. small metastasis localized deep in the liver, where a parenchyma sparing intervention is preferred over an extensive resection
3. previous extensive liver surgery
4. comorbidity
2. The multidisciplinary team should all agree that both percutaneous or open surgical MW-ablation and SBRT are safe as first treatment choice for the individual patient.
3. Tumor sizes ≤4.0 cm
4. Age \> 18 years
5. Signed informed consent
You may not be if
1. Previous radiotherapy to the liver
2. Liver volume \< 700 ml
3. Another active cancer disease within the past 36 months
4. Not able to understand written or oral protocol information
Clareo Health | Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial
